1,667
Views
6
CrossRef citations to date
0
Altmetric
Research Paper

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

, ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 1366-1373 | Received 12 Jun 2020, Accepted 10 Aug 2020, Published online: 11 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih & Jeanne-Marie Jacquet. (2022) Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Human Vaccines & Immunotherapeutics 18:5.
Read now

Articles from other publishers (5)

Jinrong Shi, Ailin Shen, Yao Cheng, Chi Zhang & Xiaoming Yang. (2023) 30-Year Development of Inactivated Virus Vaccine in China. Pharmaceutics 15:12, pages 2721.
Crossref
Rahsan Erdem, Ilse De Coster, Kanchanamala Withanage, Laina D. Mercer, Arnaud Marchant, Martin Taton, Nathalie Cools, Eva Lion, Fred Cassels, Deborah Higgins, Karen Ivinson, Emily Locke, Kutub Mahmood, Peter F. Wright, Chris Gast, Jessica A. White, Margaret E. Ackerman, Jennifer L. Konopka-Anstadt, Bernardo A. Mainou & Pierre Van Damme. (2023) Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study. Vaccine 41:10, pages 1657-1667.
Crossref
Emmanuel J. Vidor & John F. Modlin. 2023. Plotkin's Vaccines. Plotkin's Vaccines 890 913.e14 .
E. E. Evreinova, L. M. Khantimirova, V. A. Shevtsov, V. A. Merkulov & V. P. Bondarev. (2022) Promising opportunities to improve polio vaccines. Biological Products. Prevention, Diagnosis, Treatment 22:2, pages 142-153.
Crossref
Hehe Zhao, Xiaozhen Ma, Haishu Tang, Yong Zhang, Na Chen, Wusiman Kaisaier, Qi Wang, Cheng Wang, Shuangli Zhu, Qi Qi, Yu Liu, Qianli Ma, Qing Yang, Junhan Li, Dongyan Wang, Xiaolei Li, Jinbo Xiao, Hui Zhu, Wenbo Xu, Wenbin Tong & Dongmei Yan. (2021) Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018–2019. Open Forum Infectious Diseases 8:12.
Crossref